Regulation, Digitization Mulled As Swiss Medtechs Look To An ‘EU+’ Vision For The Future
Swiss Parliament addresses proposal to allow US FDA-approved products onto the market
Executive Summary
With Switzerland now operating as a third country to the EU, Swiss-based medtech manufacturers are keen to maximize their inherent advantages and build a basis for future growth.
You may also be interested in...
No MRA Means Switzerland’s Seamless IVDs Trade With The EU Is At An End
The EU’s full implementation of the In Vitro Diagnostic Regulation on 26 May has put the Swiss IVD industry on a "third country" footing with the EU, as happened in 2021 for medical devices. The two parties’ mutual recognition agreement for all medtech products has ceased to apply. A renewed MRA is not likely for several years.
Pivotal Opportunity For UK Medtech Must Not Be Wasted
The UK continues to work on its new medtech regulatory system and market access processes for innovations, but all the planning and preparations will count for little if not accompanied by sound execution, warns Lincoln Tsang of law firm Ropes & Gray.
EU MDR Extended Transitions: Practical Advice From Commission
Concerns and uncertainties arising among manufacturers following the recent extension of the MDR's transition periods have been addressed in a question-and-answer document issued by the European Commission.